Dianthus Therapeutics, Inc.
DNTH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $726 | $54 | $24 | $243 |
| - Cash | $23 | $132 | $15 | $8 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $705 | -$78 | $9 | $236 |
| Revenue | $6 | $3 | $6 | $1 |
| % Growth | 120.6% | -56% | 334.8% | – |
| Gross Profit | $6 | $3 | $6 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$101 | -$48 | -$30 | -$13 |
| % Margin | -1,627.1% | -1,692.1% | -460.6% | -886.6% |
| Net Income | -$85 | -$44 | -$28 | -$13 |
| % Margin | -1,362.8% | -1,541.2% | -443.8% | -888.1% |
| EPS Diluted | -2.55 | -8.45 | -7.6 | -3.82 |
| % Growth | 69.8% | -11.2% | -99% | – |
| Operating Cash Flow | -$78 | -$37 | -$29 | -$60 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$78 | -$37 | -$29 | -$61 |